Gaboxadol Stats & Data

Gaboxadol is a direct-acting orthosteric GABA-A agonist that preferentially engages extrasynaptic δ-subunit–containing receptors mediating tonic inhibition; this explains deep sedation with less 'benzo-like' disinhibition and has implications for combinations and reversal strategies. Because it does not act at the benzodiazepine site, flumazenil is unlikely to reverse isolated gaboxadol intoxication; management is supportive with airway monitoring, especially if other depressants were involved. High or repeated doses have been associated anecdotally and in development reports with delirium, hallucinations, and amnesia; therefore, avoid pushing beyond the common range and do not stack redoses in one night. Combination with opioids, alcohol, GHB/GBL, benzodiazepines or Z-drugs substantially increases risk for respiratory depression, loss of consciousness, and aspiration; treat these combinations as high-risk and keep doses markedly lower if abstinence from mixing is not maintained. A structural study confirms binding at α4β3δ extrasynaptic GABA-A receptors, providing mechanistic support for potent slow-wave sleep promotion and pronounced motor incoordination; practice 'safe sleep' (no baths, hazards, or tasks) and plan not to drive until fully recovered. User reports indicate variability in time to peak and next-morning grogginess; if experimenting, take the first dose on a quiet night with supervision available and no next-day obligations. A harm-reduction lab warning has identified mis-sold material contaminated with ibotenic acid (an excitotoxic Amanita alkaloid); obtain from trusted sources, consider analytical testing where available, and do not consume products of uncertain identity. Start with an allergy test (~1 mg), then space trials by several days to gauge sensitivity and tolerance build-up; tolerance to GABAergic sedatives often develops quickly and resolves slowly. As with other strong sedatives, people with sleep apnea, chronic lung disease, or unstable cardiovascular disease are at higher risk from nocturnal hypoventilation; these groups should avoid use.